Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Atropine for Myopia Control in Children
2024-513091-17-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atropine in myopia (3 arms), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Change of cycloplegic refraction/year. Planned start Oct 2024; status: authorised.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on 2024-513091-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513091-17-00.